Drugs / Autologous CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05528887 | Sep 2021 → Jun 2024 | leukemia, plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Unknown | No outcome recorded |
| Phase 1 | NCT05513612 | Aug 2020 → Dec 2025 | B-cell acute lymphoblastic leukemia, acute myeloid leukemia, adult T-cell leukemia/lymphoma, plasma cell myeloma | Shanghai Pudong Hospital | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05513612 ↗ |
| Modality | Cell therapy | “autologous CAR-T cells” NCT05513612 ↗ |
| Route | Intravenous | “CAR-T cells will be infused intravenously.” NCT05513612 ↗ |